|
Objective: Oxaliplatin is a commonly used drug for the treatment of tumors of the gastrointestinal tract , allergic reactions greatly threaten the patient 's life and health , including anaphylactic shock . The article aims to analyze and summarize the clinical features of oxaliplatin allergic reactions , and to explore the most appropriate prediction and prevention measures . Methods: clinical data of 52 cases of allergic reactions in patients with oxaliplatin , the occurrence of allergic reactions , oxaliplatin and clinical features . The result : Oxaliplatin allergic reactions occurred in 1.6% ( 52 / 3247 ) , no gender differences ( p <0.05 ) . 52 patients were type Ⅰ immediate hypersensitivity , the majority of mild to moderate allergic reactions , common symptoms of skin changes (80.8 %) , respiratory symptoms ( 76.9%) . Anaphylactic shock in 2 cases ( 3.8% ) , and found no serious immunogenic II -type hypersensitivity anemia or thrombocytopenia and deaths . The median number of courses of oxaliplatin allergic reactions occur 6 cycles ( 1-14 cycles ) , and the median cumulative dose of 580mg/m2 ( mg/m2-1900 150 mg/m2 ) . Oxaliplatin allergy sufferers in the 52 cases , 49 cases to continue to the next cycle of chemotherapy , 14 cases of recurrence of allergic reactions , including one case of anaphylactic shock . All patients after the positive symptomatic treatment , anaphylaxis symptoms in a few minutes or a few hours improved rapidly , for immunogenic fever patients may need a few days . The final 43 patients completed the planned chemotherapy plan , nine patients with chemotherapy terminated due to anaphylactic shock or who can not tolerate an allergic reaction . Conclusion : For patients with allergic reaction to a lesser extent , through the application of antihistamines and corticosteroids , measures to extend the the oxaliplatin infusion of time to ensure that the re-treatment of patients . Serious incidents of this life-threatening anaphylactic shock , oxaliplatin should be discontinued. Not only the incidence of allergic reactions in patients with allergic reactions again accept oxaliplatin significantly improved , and also increase the severity .
|